Research programme- anti-Alzheimer's therapeutics transdermal- ALZYN

Drug Profile

Research programme- anti-Alzheimer's therapeutics transdermal- ALZYN

Latest Information Update: 21 Sep 2016

Price : $50

At a glance

  • Originator Florida State University
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 20 Sep 2016 ALZYN and Transdermal Delivery Solutions enter into an agreement for licensing of a transdermal HypoSpray®-delivered solution
  • 20 Sep 2016 ALZYN in-licenses science from Florida State Research Foundation for development of transdermally administered therapeutics for Alzheimer's disease
  • 20 Sep 2016 Preclinical trials in Alzheimer's disease in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top